Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers

Summary

Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach

Timeline

Start

2014-05

Primary completion

2016-09

Completion

2016-09

Outcome

Outcome not reported

Stopped (Enrollment): “Low Accrual”

Drugs

Indications